We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Posts In-Line Q2 Earnings, View Up
Read MoreHide Full Article
MA-based Boston Scientific Corporation (BSX - Free Report) is a leading global manufacturer of medical devices that are used in a wide range of interventional medical specialties. Boston Scientific technologies address a wide range of health conditions through 7 business units that are organized into 3 global reporting segments: Rhythm Management, Cardiovascular and MedSurg.
Currently, Boston Scientific has a Zacks Rank #2 (Buy) but that could change following its second-quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at 27 cents per share over the last 30 days. Boston Scientific’s adjusted earnings of 27 cents per share came in line with this estimate.
Revenues: Boston Scientific posted revenues of $2.126 billion, comfortably beating the Zacks Consensus Estimate for revenues of $2.039 billion.
Key Stats: Boston Scientific’s Cardiovascular segment revenues increased 13% at CER to $837 million, while Rhythm Management segment’s revenue grew 5% at CER with the revenue amounting to $537 million. On the other hand, revenues from MedSurg segment improved 29% at CER to $752 million.
Major Factors: Buoyed by its strong second-quarter performance Boston Scientific has raised its 2016 revenue as well as adjusted EPS guidance. Moreover, the company received FDA approval for the Precision Montage MRI Spinal Cord Stimulator System, IntellaNav XP and the IntellaNav MiFi XP navigation-enabled ablation catheters and announced the acquisition of Cosman Medical – a manufacturer of radiofrequency ablation systems used by physicians and a handful of other updates.
Stock Price: Following the earnings release, Boston Scientific has gained 2.3% in the pre-market trading session. This reflects investors’ optimism on the results. However, the price movement during the full trading session will show whether the results have affected the market.
Check back later for our full write up on this Boston Scientific earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Posts In-Line Q2 Earnings, View Up
MA-based Boston Scientific Corporation (BSX - Free Report) is a leading global manufacturer of medical devices that are used in a wide range of interventional medical specialties. Boston Scientific technologies address a wide range of health conditions through 7 business units that are organized into 3 global reporting segments: Rhythm Management, Cardiovascular and MedSurg.
Currently, Boston Scientific has a Zacks Rank #2 (Buy) but that could change following its second-quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at 27 cents per share over the last 30 days. Boston Scientific’s adjusted earnings of 27 cents per share came in line with this estimate.
BOSTON SCIENTIF Price and EPS Surprise
BOSTON SCIENTIF Price and EPS Surprise | BOSTON SCIENTIF Quote
Revenues: Boston Scientific posted revenues of $2.126 billion, comfortably beating the Zacks Consensus Estimate for revenues of $2.039 billion.
Key Stats: Boston Scientific’s Cardiovascular segment revenues increased 13% at CER to $837 million, while Rhythm Management segment’s revenue grew 5% at CER with the revenue amounting to $537 million. On the other hand, revenues from MedSurg segment improved 29% at CER to $752 million.
Major Factors: Buoyed by its strong second-quarter performance Boston Scientific has raised its 2016 revenue as well as adjusted EPS guidance. Moreover, the company received FDA approval for the Precision Montage MRI Spinal Cord Stimulator System, IntellaNav XP and the IntellaNav MiFi XP navigation-enabled ablation catheters and announced the acquisition of Cosman Medical – a manufacturer of radiofrequency ablation systems used by physicians and a handful of other updates.
Stock Price: Following the earnings release, Boston Scientific has gained 2.3% in the pre-market trading session. This reflects investors’ optimism on the results. However, the price movement during the full trading session will show whether the results have affected the market.
Check back later for our full write up on this Boston Scientific earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>